Organ preservation strategy: new therapeutic alternative in rectal cancer
Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Safini, F. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2023 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of the Egyptian National Cancer Institute - Cairo : Inst., 2000, 35(2023), 1 vom: 24. Apr. |
|---|---|
| Übergeordnetes Werk: |
volume:35 ; year:2023 ; number:1 ; day:24 ; month:04 |
| Links: |
|---|
| DOI / URN: |
10.1186/s43046-023-00169-0 |
|---|
| Katalog-ID: |
SPR05017035X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05017035X | ||
| 003 | DE-627 | ||
| 005 | 20230425064754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230425s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43046-023-00169-0 |2 doi | |
| 035 | |a (DE-627)SPR05017035X | ||
| 035 | |a (SPR)s43046-023-00169-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Safini, F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Organ preservation strategy: new therapeutic alternative in rectal cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. | ||
| 650 | 4 | |a Organ preservation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rectal cancer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Amaoui, B. |4 aut | |
| 700 | 1 | |a Semghouli, S. |4 aut | |
| 700 | 1 | |a Aqodad, N. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Egyptian National Cancer Institute |d Cairo : Inst., 2000 |g 35(2023), 1 vom: 24. Apr. |w (DE-627)546898769 |w (DE-600)2391570-5 |x 2589-0409 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2023 |g number:1 |g day:24 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43046-023-00169-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2023 |e 1 |b 24 |c 04 | ||
| author_variant |
f s fs b a ba s s ss n a na |
|---|---|
| matchkey_str |
article:25890409:2023----::rapeevtosrtgnwhrpuiatrai |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1186/s43046-023-00169-0 doi (DE-627)SPR05017035X (SPR)s43046-023-00169-0-e DE-627 ger DE-627 rakwb eng Safini, F. verfasserin aut Organ preservation strategy: new therapeutic alternative in rectal cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. Organ preservation (dpeaa)DE-He213 Rectal cancer (dpeaa)DE-He213 Amaoui, B. aut Semghouli, S. aut Aqodad, N. aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 35(2023), 1 vom: 24. Apr. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:35 year:2023 number:1 day:24 month:04 https://dx.doi.org/10.1186/s43046-023-00169-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 35 2023 1 24 04 |
| spelling |
10.1186/s43046-023-00169-0 doi (DE-627)SPR05017035X (SPR)s43046-023-00169-0-e DE-627 ger DE-627 rakwb eng Safini, F. verfasserin aut Organ preservation strategy: new therapeutic alternative in rectal cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. Organ preservation (dpeaa)DE-He213 Rectal cancer (dpeaa)DE-He213 Amaoui, B. aut Semghouli, S. aut Aqodad, N. aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 35(2023), 1 vom: 24. Apr. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:35 year:2023 number:1 day:24 month:04 https://dx.doi.org/10.1186/s43046-023-00169-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 35 2023 1 24 04 |
| allfields_unstemmed |
10.1186/s43046-023-00169-0 doi (DE-627)SPR05017035X (SPR)s43046-023-00169-0-e DE-627 ger DE-627 rakwb eng Safini, F. verfasserin aut Organ preservation strategy: new therapeutic alternative in rectal cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. Organ preservation (dpeaa)DE-He213 Rectal cancer (dpeaa)DE-He213 Amaoui, B. aut Semghouli, S. aut Aqodad, N. aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 35(2023), 1 vom: 24. Apr. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:35 year:2023 number:1 day:24 month:04 https://dx.doi.org/10.1186/s43046-023-00169-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 35 2023 1 24 04 |
| allfieldsGer |
10.1186/s43046-023-00169-0 doi (DE-627)SPR05017035X (SPR)s43046-023-00169-0-e DE-627 ger DE-627 rakwb eng Safini, F. verfasserin aut Organ preservation strategy: new therapeutic alternative in rectal cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. Organ preservation (dpeaa)DE-He213 Rectal cancer (dpeaa)DE-He213 Amaoui, B. aut Semghouli, S. aut Aqodad, N. aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 35(2023), 1 vom: 24. Apr. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:35 year:2023 number:1 day:24 month:04 https://dx.doi.org/10.1186/s43046-023-00169-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 35 2023 1 24 04 |
| allfieldsSound |
10.1186/s43046-023-00169-0 doi (DE-627)SPR05017035X (SPR)s43046-023-00169-0-e DE-627 ger DE-627 rakwb eng Safini, F. verfasserin aut Organ preservation strategy: new therapeutic alternative in rectal cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. Organ preservation (dpeaa)DE-He213 Rectal cancer (dpeaa)DE-He213 Amaoui, B. aut Semghouli, S. aut Aqodad, N. aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 35(2023), 1 vom: 24. Apr. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:35 year:2023 number:1 day:24 month:04 https://dx.doi.org/10.1186/s43046-023-00169-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 35 2023 1 24 04 |
| language |
English |
| source |
Enthalten in Journal of the Egyptian National Cancer Institute 35(2023), 1 vom: 24. Apr. volume:35 year:2023 number:1 day:24 month:04 |
| sourceStr |
Enthalten in Journal of the Egyptian National Cancer Institute 35(2023), 1 vom: 24. Apr. volume:35 year:2023 number:1 day:24 month:04 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Organ preservation Rectal cancer |
| isfreeaccess_bool |
true |
| container_title |
Journal of the Egyptian National Cancer Institute |
| authorswithroles_txt_mv |
Safini, F. @@aut@@ Amaoui, B. @@aut@@ Semghouli, S. @@aut@@ Aqodad, N. @@aut@@ |
| publishDateDaySort_date |
2023-04-24T00:00:00Z |
| hierarchy_top_id |
546898769 |
| id |
SPR05017035X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR05017035X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230425064754.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230425s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43046-023-00169-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR05017035X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43046-023-00169-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Safini, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Organ preservation strategy: new therapeutic alternative in rectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Organ preservation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Amaoui, B.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Semghouli, S.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aqodad, N.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of the Egyptian National Cancer Institute</subfield><subfield code="d">Cairo : Inst., 2000</subfield><subfield code="g">35(2023), 1 vom: 24. Apr.</subfield><subfield code="w">(DE-627)546898769</subfield><subfield code="w">(DE-600)2391570-5</subfield><subfield code="x">2589-0409</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:24</subfield><subfield code="g">month:04</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43046-023-00169-0</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">24</subfield><subfield code="c">04</subfield></datafield></record></collection>
|
| author |
Safini, F. |
| spellingShingle |
Safini, F. misc Organ preservation misc Rectal cancer Organ preservation strategy: new therapeutic alternative in rectal cancer |
| authorStr |
Safini, F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)546898769 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2589-0409 |
| topic_title |
Organ preservation strategy: new therapeutic alternative in rectal cancer Organ preservation (dpeaa)DE-He213 Rectal cancer (dpeaa)DE-He213 |
| topic |
misc Organ preservation misc Rectal cancer |
| topic_unstemmed |
misc Organ preservation misc Rectal cancer |
| topic_browse |
misc Organ preservation misc Rectal cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of the Egyptian National Cancer Institute |
| hierarchy_parent_id |
546898769 |
| hierarchy_top_title |
Journal of the Egyptian National Cancer Institute |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)546898769 (DE-600)2391570-5 |
| title |
Organ preservation strategy: new therapeutic alternative in rectal cancer |
| ctrlnum |
(DE-627)SPR05017035X (SPR)s43046-023-00169-0-e |
| title_full |
Organ preservation strategy: new therapeutic alternative in rectal cancer |
| author_sort |
Safini, F. |
| journal |
Journal of the Egyptian National Cancer Institute |
| journalStr |
Journal of the Egyptian National Cancer Institute |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| author_browse |
Safini, F. Amaoui, B. Semghouli, S. Aqodad, N. |
| container_volume |
35 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Safini, F. |
| doi_str_mv |
10.1186/s43046-023-00169-0 |
| title_sort |
organ preservation strategy: new therapeutic alternative in rectal cancer |
| title_auth |
Organ preservation strategy: new therapeutic alternative in rectal cancer |
| abstract |
Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. © The Author(s) 2023 |
| abstractGer |
Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. © The Author(s) 2023 |
| abstract_unstemmed |
Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex. © The Author(s) 2023 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
1 |
| title_short |
Organ preservation strategy: new therapeutic alternative in rectal cancer |
| url |
https://dx.doi.org/10.1186/s43046-023-00169-0 |
| remote_bool |
true |
| author2 |
Amaoui, B. Semghouli, S. Aqodad, N. |
| author2Str |
Amaoui, B. Semghouli, S. Aqodad, N. |
| ppnlink |
546898769 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s43046-023-00169-0 |
| up_date |
2024-07-03T13:49:59.550Z |
| _version_ |
1803566028747177984 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR05017035X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230425064754.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230425s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43046-023-00169-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR05017035X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43046-023-00169-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Safini, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Organ preservation strategy: new therapeutic alternative in rectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The therapeutic modalities for nonmetastatic rectal cancer are presently undergoing major changes. The standard treatment is multidisciplinary, combining radiotherapy, chemotherapy, and surgery. The aim of this minireview is to provide an update on the place of organ preservation in the treatment of nonmetastatic rectal cancer in 2022. Main text The multimodal strategy based on initial radiochemotherapy followed by radical surgery with excision of the mesorectum has improved oncological results but at the expense of morbidity and sequelae altering life quality. The strategy of rectal preservation has been proposed since the 2000s after the publication of the results of the Brazilian study that proposed a simple surveillance after radiochemotherapy without surgery in good responders. In fact, preoperative radiochemotherapy was able to obtain a complete histological response in 10 to 30% of case. In view of this non-negligible percentage of tumor sterilization, which may well increase with the standardization of total neoadjuvant treatment, a strategy of organ preservation can be proposed in these patients to avoid morbidity and postoperative sequelae. Short conclusion This nonoperative approach is currently widely studied in certain patients who have a complete response (clinical, endoscopic, and radiological). However, the selection of these patients is not simple and still complex.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Organ preservation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Amaoui, B.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Semghouli, S.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aqodad, N.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of the Egyptian National Cancer Institute</subfield><subfield code="d">Cairo : Inst., 2000</subfield><subfield code="g">35(2023), 1 vom: 24. Apr.</subfield><subfield code="w">(DE-627)546898769</subfield><subfield code="w">(DE-600)2391570-5</subfield><subfield code="x">2589-0409</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:24</subfield><subfield code="g">month:04</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43046-023-00169-0</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">24</subfield><subfield code="c">04</subfield></datafield></record></collection>
|
| score |
7.400522 |